How to manage Waldenstrom’s macroglobulinemia
Open Access
- 6 February 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (4), 762-772
- https://doi.org/10.1038/leu.2013.36
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumabBlood, 2011
- Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's MacroglobulinemiaClinical Cancer Research, 2010
- microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaBlood, 2009
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944